Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100.

There was a nonsignificant trend toward enrichment of longer benefit with PD-L1 tumor proportion score (TPS) <1% versus ≥1% (odds ratio [OR], 0.36 [0.12 to 1.12]), without significant differences between PD-L1 TPS 1%-49% and ≥50% (OR, 0.83 [0.07 to 9.69]).

also in 5,406 other papers